A key selling point of the drug known as Dabigatran or Pradaxa was that it required no blood-level monitoring, as does competitor warfarin. Dabigatran's maker, Boehringer Ingelheim, had said the drug was better than warfarin at reducing stroke in people with irregular heart rhythm, with a similar risk of major bleeds, according to the British Medical Journal (BMJ). Based on its own probe, the journal accused Boehringer of concealing information that blood-level monitoring could in fact reduce major bleeds by up to 30-40 percent compared to warfarin. According to BMJ investigations editor Deborah Cohen, who conducted the research, millions of people take the anti-clotting drug, with blood levels found to vary greatly between patients.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment